The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis.
C. Gisselbrecht
Research Funding - Baxter International; Roche
B. Glass
Research Funding - Roche
G. Laurent
No relevant relationships to disclose
D. S. Gill
No relevant relationships to disclose
M. D. Linch
Consultant or Advisory Role - Chugai Pharma; Roche
Honoraria - Roche
Research Funding - Roche
M. Trneny
Research Funding - Roche
D. Bron
No relevant relationships to disclose
O. Shpilberg
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
H. Hagberg
No relevant relationships to disclose
M. Bargetzi
No relevant relationships to disclose
D. Ma
Research Funding - Roche
J. Briere
No relevant relationships to disclose
C. Moskowitz
Research Funding - Genentech
N. Schmitz
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Baxter International; Roche